Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule (110 mg and 150 mg b.i.d., 7 Days) in Healthy Japanese and Caucasian Male Subjects (Open Label Study)
Latest Information Update: 27 Jun 2014
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Deep vein thrombosis; Embolism; Stroke; Venous thromboembolism
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 27 Jun 2014 New trial record